Apply!

Apply today to the PSCC and benefit from the PSCC offer. Applications are evaluated on a rolling basis as they come in. Through the Support and Orientation Office (SOO) team, the cluster provides you access to all the resources that condition the success of innovation in oncology: talents, technologies, network, financing, spaces, patients and associated data. By vocation and by culture, the PSCC brings together disciplines (biology, mathematics, physics, artificial intelligence, etc.) and fields of application (therapeutics, diagnostics, medical devices, digital health).

Find out more about the PSCC offer

For who ?

We enthusiastically invite projects from a wide range of companies, from start-ups to mature companies, encompassing both those in the nascent preclinical stage and those advancing through early clinical phases. These projects span the entire oncology landscape and include a wide range of innovative solutions: therapies, diagnostics, and medical devices. We support French as well as international companies contributing to the French economy.

A selective approach

The PSCC concentrates its resources where it can make a difference, that is on projects (ideation, creation, pre-seed, seed, acceleration) that are scientifically creative and have very high diagnostic or therapeutic potential. To capture the best of discovery and innovation, it relies on a rigorous selection process and an independent evaluation committee made up of experienced scientists and entrepreneurs. Depending on their ranking, the selected projects benefit from all or part of the PSCC's offer.

"If your project is selected, the role of the Support and Orientation Office (SOO) will be to coach and support your team, to coordinate interactions with the partners scientific offer and to facilitate connections with experts and potential partners.

Lucie Mondoulet, PhD. Member of the SOO

To apply

Fill out the form (link below) and upload your presentation.

Each project's applicant must provide a powerpoint/PDF file presentation in English, with 12 slides maximum, including non-confidential items listed below:

Slide 1: Executive Summary
Slide 2: Problem/targeted patient need addressed by the project
Slide 3: Solution offered
Slides 4-6 : The science behind the solution, with a focus on IP
Slide 7: Team
Slide 8: Roadmap (Gantt Chart type: milestones achieved and milestones to come)
Slide 9: Expectations and commitments to the PSCC
Slide 10: List of competitors and differentiating features
Slide 11 : Existing funding (secured and/or in progress)
Slide 12 : Existing support (SATT, incubator, advisors, etc.)

The SOO may contact you to obtain additional information based on your request.

Access the form

sélection

Our selection criteria

Your application will be processed by the SOO and evaluated by an independent committee,taking into account the project's maturity.

Aim: identify the projects that have the most potential for acceleration by the PSCC.

30%

Quality of
the team

Credibility of the scientific team (training, publications, experience, etc.)
Ability of the team to lead the development project and/or to be accompanied
Motivation and openness to external contributions

40%

Quality of
Science

Robustness of the first results
Innovation level
Consistency of the scientific strategy
Securing intellectual property

20%

Need to be covered / development opportunities

Patient need not or poorly covered
Life-changing potential for patients
Consistency and credibility of the development plan

10%

Contribution to cluster objectives

Partial or total location on the cluster site, use of several aspects of the offer, commitment to contribute...
Job creation potential in France

By joining the PSCC, you will have the opportunity to join a community of promising projects supported by the PSCC and benefit from a wide range of resources crucial to accelerate your success in fighting against cancer.

They are among the first companies to have access to the PSCC support:

‘‘ We received from the PSCC a valuable support, including training for our staff and the connexion to leading experts to help us in optimizing our clinical development strategy.’’

Apmonia Therapeutics:

A biotech company developing a first-in-class pipeline of next-generation peptide-based therapies targeting the extracellular matrix to reprogram the tumor microenvironment.